Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer
NCT02551432
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
26
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
pembrolizumab, paclitaxel
Sponsor
Seoul National University Hospital